Alkermes Plc (ALKS) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Alkermes Plc   (NASDAQ: ALKS)


Alkermes Plc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALKS Gross Profit Margin (Sep 30 2026)
Q3 		(Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Revenue Change 21.8 %
Seq. Revenue Change -3.2 %
Revenue In Millions $480.13
Gross Profit Margin 80.38 %
Gross Profit Margin Total Ranking # 532
Gross Profit In Millions $385.91
Y / Y Gross Profit Change 12.64 %
Seq. Gross Profit Change -3.01 %


Commenting Third Quarter 2026 Gross Profit Margin
Alkermes Plc increased Gross Profit Margin through reduction in Cost of Sales and despite contraction in Gross Profit by -3.01 % and Revenue by -3.2 %. Gross Profit Margin in Q3 was 80.38 %, below company average.


Observing third quarter 2026 results within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 459 to 532.
Learn about Gross Margin
ALKS's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 54
Healthcare Sector # 89
Overall # 528

Gross Profit Margin Statistics
High Average Low
93.31 % 80.55 % 65.97 %
(Dec 31 2018)   (Dec 31 2011)


ALKS Gross Income Trends • More of ALKS's Profitabilty Ratios • ALKS Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ALKS's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ALKS's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ALKS's Competitors
Gross Profit Margin Profit Margin for Alkermes Plc 's Suppliers
Gross Profit Margin Profit Margin for ALKS's Customers

You may also want to know
ALKS's Annual Growth Rates ALKS's Profitability Ratios ALKS's Asset Turnover Ratio ALKS's Dividend Growth
ALKS's Roe ALKS's Valuation Ratios ALKS's Financial Strength Ratios ALKS's Gross Profit Growth
ALKS's Roa ALKS's Inventory Turnover Ratio ALKS's Growth Rates ALKS's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Protagonist Therapeutics inc   99.60 %$ 273.310  Millions$ 274.410  Millions
Lexicon Pharmaceuticals Inc   99.30 %$ 11.171  Millions$ 11.250  Millions
Verastem Inc   98.84 %$ 23.733  Millions$ 24.012  Millions
Travere Therapeutics Inc   98.72 %$ 221.696  Millions$ 224.563  Millions
Adc Therapeutics Sa  98.67 %$ 21.428  Millions$ 21.716  Millions
Corcept Therapeutics Inc  98.65 %$ 335.864  Millions$ 340.472  Millions
Ionis Pharmaceuticals Inc   98.63 %$ 239.399  Millions$ 242.721  Millions
Kura Oncology Inc   98.38 %$ 22.468  Millions$ 22.839  Millions
Ardelyx inc   96.44 %$ 123.116  Millions$ 127.655  Millions
Uniqure N v   95.46 %$ 4.960  Millions$ 5.196  Millions
Agios Pharmaceuticals Inc   95.44 %$ 52.860  Millions$ 55.385  Millions
Zevra Therapeutics Inc   95.25 %$ 35.962  Millions$ 37.756  Millions
Bridgebio Pharma Inc   94.21 %$ 332.721  Millions$ 353.171  Millions
Gyre Therapeutics Inc   94.09 %$ 30.987  Millions$ 32.934  Millions
Vanda Pharmaceuticals Inc   94.05 %$ 65.663  Millions$ 69.815  Millions
Axsome Therapeutics Inc   93.14 %$ 241.887  Millions$ 259.691  Millions
Tonix Pharmaceuticals Holding Corp   92.74 %$ 15.982  Millions$ 17.234  Millions
Urogen Pharma Ltd   91.57 %$ 81.499  Millions$ 89.001  Millions
Arcutis Biotherapeutics Inc   91.34 %$ 131.459  Millions$ 143.919  Millions
Roivant Sciences Ltd   90.47 %$ 31.774  Millions$ 35.121  Millions
Kiniksa Pharmaceuticals International Plc  90.29 %$ 258.211  Millions$ 285.970  Millions
Aurinia Pharmaceuticals Inc   90.08 %$ 75.393  Millions$ 83.699  Millions
Acadia Pharmaceuticals Inc   89.75 %$ 307.201  Millions$ 342.291  Millions
Mannkind Corporation  88.99 %$ 90.657  Millions$ 101.870  Millions
Regeneron Pharmaceuticals Inc   88.79 %$ 4,542.200  Millions$ 5,115.800  Millions
Ocular Therapeutix Inc   88.70 %$ 11.419  Millions$ 12.874  Millions
Beone Medicines Ltd   88.52 %$ 1,672.919  Millions$ 1,889.815  Millions
Xeris Biopharma Holdings Inc   88.41 %$ 94.796  Millions$ 107.225  Millions
United Therapeutics Corporation  88.10 %$ 733.400  Millions$ 832.500  Millions
Supernus Pharmaceuticals inc   88.09 %$ 199.753  Millions$ 226.771  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.